Literature DB >> 30140960

Epigenetic mechanisms of tumor resistance to immunotherapy.

Natalia Arenas-Ramirez1, Dilara Sahin2, Onur Boyman3,4.   

Abstract

The recent impact of cancer immunotherapies has firmly established the ability and importance of the immune system to fight malignancies. However, the intimate interaction between the highly dynamic tumor and immune cells leads to a selection process driven by genetic and epigenetic processes. As the molecular pathways of cancer resistance mechanisms to immunotherapy become increasingly known, novel therapeutic targets are being tested in combination with immune-stimulating approaches. We here review recent insights into the molecular mechanisms of tumor resistance with particular emphasis on epigenetic processes and place these in the context of previous models.

Entities:  

Keywords:  CTLA-4; Checkpoint inhibitor; Cytokine; EED; EZH2; IL-2; Immunogenicity; PD-1; PRC2; Tumor escape

Mesh:

Substances:

Year:  2018        PMID: 30140960     DOI: 10.1007/s00018-018-2908-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  138 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

2.  A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Authors:  Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

3.  The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin.

Authors:  Merry Gunawan; Nandini Venkatesan; Jia Tong Loh; Jong Fu Wong; Heidi Berger; Wen Hao Neo; Liang Yao Jackson Li; Myint Khun La Win; Yin Hoe Yau; Tiannan Guo; Peter Chi Ee See; Sayuri Yamazaki; Keh Chuang Chin; Alexandre R Gingras; Susana Geifman Shochat; Lai Guan Ng; Siu Kwan Sze; Florent Ginhoux; I-hsin Su
Journal:  Nat Immunol       Date:  2015-03-09       Impact factor: 25.606

4.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development.

Authors:  Naganari Ohkura; Masahide Hamaguchi; Hiromasa Morikawa; Kyoko Sugimura; Atsushi Tanaka; Yoshinaga Ito; Motonao Osaki; Yoshiaki Tanaka; Riu Yamashita; Naoko Nakano; Jochen Huehn; Hans Joerg Fehling; Tim Sparwasser; Kenta Nakai; Shimon Sakaguchi
Journal:  Immunity       Date:  2012-11-01       Impact factor: 31.745

Review 5.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

6.  Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways.

Authors:  Federica Natoni; Laura Diolordi; Claudio Santoni; Maria Saveria Gilardini Montani
Journal:  Biochim Biophys Acta       Date:  2005-09-30

Review 7.  Interleukin-2: Biology, Design and Application.

Authors:  Natalia Arenas-Ramirez; Janine Woytschak; Onur Boyman
Journal:  Trends Immunol       Date:  2015-11-10       Impact factor: 16.687

8.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

Review 9.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

Review 10.  Augmenting antitumor immune responses with epigenetic modifying agents.

Authors:  Erika Héninger; Timothy E G Krueger; Joshua M Lang
Journal:  Front Immunol       Date:  2015-02-04       Impact factor: 7.561

View more
  8 in total

Review 1.  Emerging Therapies in Penile Cancer.

Authors:  Antonio Machado Alencar; Guru Sonpavde
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

2.  An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer.

Authors:  Dilara Sahin; Natalia Arenas-Ramirez; Matthias Rath; Ufuk Karakus; Monika Hümbelin; Merel van Gogh; Lubor Borsig; Onur Boyman
Journal:  Nat Commun       Date:  2020-12-22       Impact factor: 14.919

3.  LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance.

Authors:  Weiwei Guo; Yue Wang; Min Yang; Zehua Wang; Yifei Wang; Smriti Chaurasia; Zhiyuan Wu; Min Zhang; Ghanshyam Singh Yadav; Sanjay Rathod; Fernando Concha-Benavente; Christian Fernandez; Song Li; Wen Xie; Robert L Ferris; Udai S Kammula; Binfeng Lu; Da Yang
Journal:  Sci Adv       Date:  2021-02-10       Impact factor: 14.136

Review 4.  HDAC Inhibition to Prime Immune Checkpoint Inhibitors.

Authors:  Edith Borcoman; Maud Kamal; Grégoire Marret; Celia Dupain; Zahra Castel-Ajgal; Christophe Le Tourneau
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 5.  Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.

Authors:  Xunrui Chen; Wenhui Zhang; Wenyan Yang; Min Zhou; Feng Liu
Journal:  Aging (Albany NY)       Date:  2022-01-17       Impact factor: 5.682

Review 6.  Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.

Authors:  Sarah E Fenton; Jeffrey A Sosman; Sunandana Chandra
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 7.  The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".

Authors:  Thomas Strub; Robert Ballotti; Corine Bertolotto
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 8.  Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers.

Authors:  Meng Li; Denis Kaili; Lei Shi
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.